On 1 November 2022, the High Court of Delhi disposed of a writ petition asking for directions to the government to allow use of homoeopathic medicines for treating COVID-19.

The petitioners had filed a public interest litigation asking for several orders to be issued, including: (i) direction to the competent ministry to notify a homoeopathic drug as a preventive drug for COVID-19; and (ii) direction to the government to allow practitioners to treat mild COVID cases with homoeopathic medicines.

The court pointed out that, during the pandemic, the government issued protocols and guidelines to control the pandemic through expert bodies such as the Indian Council of Medical Research. Such expert bodies and other statutory bodies are the most qualified to determine the content of such protocols and the court cannot comment decisions taken after extensive research.

News available at en